---
title: Certara vs Syngene International
slug_a: certara
slug_b: syngeneintl
site: cro
review_signal_gate: closed
canonical_path: /compare/certara/syngeneintl
generated_by: BioBM Editorial AI
---

# Certara vs Syngene International

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

Certara (certara) is listed for cro. Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.

Services: 37. Modalities: 20. Indications: 25. Locations: 8. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (37).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

Syngene International (syngeneintl) is listed for both. Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.

Services: 100. Modalities: 10. Indications: 14. Locations: 3. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (100).

Review summary: Review summary withheld until site-level review gate opens.